A carregar...
Development of a Ternary Solid Dispersion Formulation of LW6 to Improve the In Vivo Activity as a BCRP Inhibitor: Preparation and In Vitro/In Vivo Characterization
LW6 (3-[2-(4-adamantan-1-yl-phenoxy)-acetylamino]-4-hydroxy-benzoic acid methyl ester) is a potent inhibitor of drug efflux by the breast cancer resistance protein (BCRP). However, its poor aqueous solubility leads to low bioavailability, which currently limits in vivo applications. Therefore, the p...
Na minha lista:
| Publicado no: | Pharmaceutics |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6572573/ https://ncbi.nlm.nih.gov/pubmed/31052438 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/pharmaceutics11050206 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|